Anticoagulants Market worth over $51.9bn by 2027
Published Date: March 5, 2021 Authors: Sumant Ugalmugle, Rupali Swain
Anticoagulants Market size is set to surpass USD 51.9 billion by 2027, according to a new research report by Global Market Insights, Inc.
Increasing incidence of coagulation disorders coupled with substantial growth in the number of individuals suffering from chronic diseases will drive the market growth. According to the Center for Disease Control and Prevention (CDC) report, approximately 900,000 individuals are affected by pulmonary embolism and deep vein thrombosis each year in the U.S. Such high pervasiveness of thromboembolism will increase the demand for anticoagulation treatment and is expected to propel the market expansion across the globe.
Increasing geriatric population across the globe will spur the market value
Geriatric population is prone to various chronic diseases such as deep vein thrombosis and pulmonary embolism that will positively influence the market revenue. Also, stroke is likely caused by blood clot that interrupts blood flow in the brain. The prevalence of stroke in geriatric population is 2% to 5% across the globe. Similarly, as per the World Stroke Organization report, around 60% of all DVT occurs in people over 50 years of age. Thus, rising incidence of stroke and DVT diseases across the world will increase the demand and is projected to drive the market demand. Furthermore, focus of market players on highly precise and upgraded anticoagulant products will augment the industry growth.
Stringent regulatory framework may hamper the anticoagulants market size
Complex regulatory landscape may act as a barrier in the industry expansion. The pharmaceutical and biotechnology industry is one of the highly regulated industries with various regulatory norms and many rules enforced by government to protect well-being and health of the public. For instance, the regulation of anticoagulant drugs assures safety and efficacy of drugs while providing rapid movement of innovative therapies through the investigative and regulatory processes. However, the process is too lengthy and often complex in nature. Thus, complex guidelines laid by various regulatory bodies for the safety and efficacy of anticoagulant drugs may slower the approval of new products, thereby limiting the market growth.
Various application of direct thrombin inhibitors for blood clotting disorder treatment will foster the industry revenue
The direct thrombin inhibitor segment accounted for 12.9% of the market share in 2020. Direct thrombin inhibitors are a novel class of drugs that have been developed as an effective alternative mode of anticoagulation. The drug is primarily used in patients suffering from heparin?induced thrombocytopaenia, who require dialysis, and for the management of thromboembolic disorders as well as acute coronary syndromes. Such applications of direct thrombin inhibitor for blood clotting disorders will augment the segment growth. Additionally, several novel direct thrombin inhibitors are in late-stage development for treatment of various disease condition that will boost the industry value.
Browse key industry insights spread across 150 pages with 229 market data tables & 18 figures & charts from the report, “Anticoagulants Market Size By Drug Class (Factor Xa Inhibitors, Heparins, Warfarin, Direct Thrombin Inhibitors), By Route of Administration (Oral, Injectables), By Application (Venous Thromboembolism, Atrial Fibrillation/Flutter, Coronary Heart Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027” in detail along with the table of contents:
Advantages associated with oral anticoagulants will propel the market demand
The oral segment accounted for USD 14.2 billion in 2020. Oral anticoagulant drugs such as rivaroxaban, dabigatran and apixaban prevent blood clots and are widely used to treat patients and reduce the overall risk of stroke related atrial fibrillation. Also, these drugs have better bioavailability and minimal drug interaction. Such advantages associated with oral anticoagulants will influence the market growth during the forecast period.
Increasing prevalence of atrial fibrillation will positively impact the segment expansion
The atrial fibrillation segment exceeded for USD 9.3 billion in 2020 led by rising prevalence of atrial fibrillation, as the risk of blood clot formation in heart may increase to five times. This may lead to increase in product demand, thereby supplementing the segment revenue. In addition, growing geriatric population that are prone to various chronic illnesses will significantly enhance the market expansion over the forthcoming years.
High adoption of anticoagulant drugs in various chronic diseases as well as availability at retail stores at discounted price will impel the segment value
The retail pharmacy distribution channel will exhibit 6.7% growth rate to reach USD 17.2 billion by 2027 due to utilization of anticoagulant drugs in treatment of various diseases along with availability of drugs at retail stores. Also, rising demand of surgical procedures that require anticoagulant drugs will fuel the market revenue. Furthermore, increasing cases of chronic diseases such as deep vein thrombosis and myocardial infraction will upsurge the demand for anticoagulants.
Presence of key industry players in the European region will foster the market growth
Europe anticoagulants market size was USD 6.6 billion in 2020 and is estimated to attain a CAGR of 4.2% till 2027. Presence of market players focusing to expand their business in anticoagulants division coupled with well-established distribution network will drive the regional growth. Moreover, rising elderly population that is prone to coronary artery diseases and venous thromboembolism will boost the regional expansion.
Companies undertake inorganic growth strategies to strengthen their business portfolio and revenue
The eminent companies operating in the market include Bristol-Myers Sqiubb, Amphastar Pharmaceutical, Sanofi, Hepalink group, Pfizer, Leo Pharma, Laboratories Farmaceuticos Rovi SA among others. These industry participants focus on strategies such as acquisitions & mergers, innovative product development and partnerships to garner more revenue and sustain market competition.